Icosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121

Benzinga ·  08/09/2023 05:56

In new data from Icosavax's IVX-121 Phase 1b extension trial in older adults, GMTs against RSV through day 365 persisted at ~45-70% of the GMTs at day 28 (for 75 and 250 μg unadjuvanted dosages) -- Data provide additional clinical evidence of potential differentiation on durability with company's VLP platform technology -- Robust immune response against RSV-A observed in Phase 1b extension trial participants who were revaccinated with IVX-121 twelve months following initial dose -- IVX-121 continues to be generally well tolerated with no additional safety concerns observed with longer-term follow up or revaccination -- IVX-A12 (a potential-first-in-class bivalent combination of IVX-121 for RSV

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment